课题基金 / 基金详情

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
替莫唑胺
批准号:
6303480
负责人:
HARRY S GREENBERG
金额:
$0.02万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-12-01 至 2001-02-28

项目摘要

项目成果

HARRY S GREENBERG的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The purpose of this study is to determine how patients with brain tumors respond to the combination of the chemotherapy drugs temozolomide and BCNU, and how long their response lasts when treated with this combination. If this treatment works, it may cause your tumor to shrink and prolong your life and/or improve the quality of your life. We also want to find out what kind of side effects these drugs cause in combination and how often they occur. Patients with glioblastoma multiforme, a type of malignant glioma, must have failed treatment with surgery and radiation and may or may not have chemotherapy. Patients with anaplastic glioma must not have had postoperative treatment with radiation or chemotherapy. Patients will receive treatments every six weeks and will be followed with MRI scans for response determination.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS
MARIMASTAT IN PATIENTS W/ GLIOBLASTOMA MULTIFORME OF GLIOSARCOMA
海外基金